Bulletin
Investor Alert

New York Markets Open in:

Incyte Corp.

NAS: INCY

GO
/marketstate/country/us

After Hours

/zigman2/quotes/204510994/composite

$

78.51

Change

0.00 0.00%

Volume

Volume 64,018

Oct 22, 2019, 5:50 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/204510994/composite

Previous close

$ 78.59

$ 78.51

Change

-0.08 -0.10%

Day low

Day high

$78.36

$80.37

Open
Open: 78.76

52 week low

52 week high

$57.00

$89.30

Open

Market cap

$16.88B

Average volume

1.08M

P/E ratio

55.51

Rev. per Employee

$1.38M

EPS

1.41

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/incy

MarketWatch News on INCY

  1. Incyte rerpots positive results in trial of treatment for GVHD

    7:04 a.m. Oct. 16, 2019

    - Ciara Linnane

  2. Incyte shares up 1.2% premarket

    7:05 a.m. Oct. 16, 2019

    - Ciara Linnane

  3. European Conference Highlights Cancer-Drug Developments

    7:00 a.m. Oct. 3, 2019

    - Barron's Online

  4. The 3 Best Health-Care Stocks This Month. And the Worst

    6:00 a.m. Sept. 30, 2019

    - Barron's Online

  5. A Big Cancer Conference Could Yield Breakthroughs

    7:10 a.m. Oct. 1, 2019

    - Barron's Online

  6. Incyte upgraded to outperform from perform at Oppenheimer

    8:31 a.m. Sept. 5, 2019

    - Tomi Kilgore

  7. Incyte stock price target raised to $100 from $85 at Oppenheimer

    8:31 a.m. Sept. 5, 2019

    - Tomi Kilgore

  8. 3 stocks that can make you money despite a trade war or recession

    7:31 a.m. July 21, 2019

    - Philip van Doorn

  9. Incyte enters license deal with Zai Lab for commercialization of Incyte's cancer treatment in China

    7:35 a.m. July 2, 2019

    - Tomi Kilgore

  10. The Dow Is Treading Lightly Ahead of a Possible Fed Rate Cut

    5:50 p.m. June 17, 2019

    - Barron's Online

  11. What to expect when Merck reports earnings Tuesday

    1:41 p.m. April 29, 2019

    - Sarah Toy

  12. Loading more headlines...
/news/nonmarketwatch/company/us/incy

Other News on INCY

  1. What's in the Cards for AstraZeneca (AZN) in Q3 Earnings?

    12:14 p.m. Oct. 21, 2019

    - Zacks.com

  2. Nokia (NOK) to Report Q3 Earnings: What's in the Offing?

    9:43 a.m. Oct. 21, 2019

    - Zacks.com

  3. Novartis' Jakavi Meets Primary Goal in Phase III for GVHD

    12:12 p.m. Oct. 17, 2019

    - Zacks.com

  4. Incyte Corp (INCY) Received its Third Buy in a Row

    11:10 a.m. Oct. 16, 2019

    - SmarterAnalyst

  5. Incyte's Jakafi successful in late-stage GvHD study

    7:50 a.m. Oct. 16, 2019

    - Seeking Alpha

  6. Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA

    10:57 a.m. Oct. 15, 2019

    - Zacks.com

  7. Seattle Genetics Begins Phase III Study on Tucatinib Combo

    12:40 p.m. Oct. 11, 2019

    - Zacks.com

  8. 10 Great Biotech Stocks to Buy in Q4

    12:17 p.m. Oct. 7, 2019

    - InvestorPlace.com

  9. Incyte Sees Hammer Chart Pattern: Time to Buy?

    5:28 a.m. Oct. 4, 2019

    - Zacks.com

  10. Loading more headlines...
/news/pressrelease/company/us/incy

Press Releases on INCY

  1. Incyte to Present at Upcoming Investor Conference

    8:00 a.m. Oct. 22, 2019

    - BusinessWire - BZX

  2. Incyte to Report Third Quarter Financial Results

    8:00 a.m. Oct. 10, 2019

    - BusinessWire - BZX

  3. Loading more headlines...

Rates »

Link to MarketWatch's Slice.